How much profit has AB Science made this year?
AB Science has made -11.33 M EUR this year.
AB Science Net Income 2024
AB Science Net Income
-11.33 M EUR
Ticker
AB.PA
ISIN
FR0010557264
WKN
A1CXBG
In 2024, AB Science's profit amounted to -11.33 M EUR, a -5.48% increase from the -11.99 M EUR profit recorded in the previous year.
The AB Science Net Income history
| YEAR | NET INCOME (undefined EUR) |
|---|---|
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | - |
| 2009 | - |
| 2008 | - |
| 2007 | - |
AB Science Revenue, EBIT, Net Income FR0010557264 · A1CXBG
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into AB Science, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AB Science from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AB Science’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of AB Science. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into AB Science’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing AB Science’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AB Science’s growth potential.
AB Science Revenue, EBIT and net profit per share
| Date | AB Science Revenue | AB Science EBIT | AB Science Net Income |
|---|---|---|---|
| 2026e | 1.24 M undefined | -16.32 M undefined | -9.25 M undefined |
| 2025e | 1.14 M undefined | -16.42 M undefined | -10.89 M undefined |
| 2024e | 824,000 undefined | 0 undefined | -11.33 M undefined |
| 2023 | 970,000 undefined | -13.43 M undefined | -11.99 M undefined |
| 2022 | 958,000 undefined | -15.94 M undefined | -13.62 M undefined |
| 2021 | 1.61 M undefined | -13.81 M undefined | -14.46 M undefined |
| 2020 | 1.58 M undefined | -14.75 M undefined | -15.05 M undefined |
| 2019 | 1.57 M undefined | -17.47 M undefined | -21.75 M undefined |
| 2018 | 1.7 M undefined | -28.94 M undefined | -26.06 M undefined |
| 2017 | 1.74 M undefined | -28.4 M undefined | -27.12 M undefined |
| 2016 | 1.51 M undefined | -30.21 M undefined | -27.7 M undefined |
| 2015 | 2.28 M undefined | -25.96 M undefined | -26.72 M undefined |
| 2014 | 2.1 M undefined | -15.2 M undefined | -16.11 M undefined |
| 2013 | 1.93 M undefined | -13.77 M undefined | -14.61 M undefined |
| 2012 | 1.34 M undefined | -10.61 M undefined | -10.99 M undefined |
| 2011 | 1.1 M undefined | -9.72 M undefined | -9.65 M undefined |
| 2010 | 1.18 M undefined | -9.59 M undefined | -9.49 M undefined |
| 2009 | 320,000 undefined | -8.3 M undefined | -8.11 M undefined |
| 2008 | 0 undefined | -8 M undefined | -7.45 M undefined |
| 2007 | 0 undefined | -7.15 M undefined | -6.53 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2007 | 0 EUR | -7.15 M EUR | -6.53 M EUR |
| 2008 | 0 EUR | -8 M EUR | -7.45 M EUR |
| 2009 | 320,000 EUR | -8.3 M EUR | -8.11 M EUR |
| 2010 | 1.18 M EUR | -9.59 M EUR | -9.49 M EUR |
| 2011 | 1.1 M EUR | -9.72 M EUR | -9.65 M EUR |
| 2012 | 1.34 M EUR | -10.61 M EUR | -10.99 M EUR |
| 2013 | 1.93 M EUR | -13.77 M EUR | -14.61 M EUR |
| 2014 | 2.1 M EUR | -15.2 M EUR | -16.11 M EUR |
| 2015 | 2.28 M EUR | -25.96 M EUR | -26.72 M EUR |
| 2016 | 1.51 M EUR | -30.21 M EUR | -27.7 M EUR |
| 2017 | 1.74 M EUR | -28.4 M EUR | -27.12 M EUR |
| 2018 | 1.7 M EUR | -28.94 M EUR | -26.06 M EUR |
| 2019 | 1.57 M EUR | -17.47 M EUR | -21.75 M EUR |
| 2020 | 1.58 M EUR | -14.75 M EUR | -15.05 M EUR |
| 2021 | 1.61 M EUR | -13.81 M EUR | -14.46 M EUR |
| 2022 | 958,000 EUR | -15.94 M EUR | -13.62 M EUR |
| 2023 | 970,000 EUR | -13.43 M EUR | -11.99 M EUR |
| 2024e | 824,000 EUR | 0 EUR | -11.33 M EUR |
| 2025e | 1.14 M EUR | -16.42 M EUR | -10.89 M EUR |
| 2026e | 1.24 M EUR | -16.32 M EUR | -9.25 M EUR |
AB Science stock margins FR0010557264 · A1CXBG
The AB Science margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AB Science. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AB Science.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the AB Science's sales revenue. A higher gross margin percentage indicates that the AB Science retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the AB Science's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the AB Science's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AB Science's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AB Science. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AB Science's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
AB Science Margin History
| AB Science Gross margin | AB Science Profit margin | AB Science EBIT margin | AB Science Profit margin |
|---|---|---|---|
| 2026e | 60.52 % | -1,319.09 % | -747.92 % |
| 2025e | 60.52 % | -1,436.66 % | -952.44 % |
| 2024e | 60.52 % | 0 % | -1,374.84 % |
| 2023 | 60.52 % | -1,384.43 % | -1,235.57 % |
| 2022 | 96.76 % | -1,663.57 % | -1,421.19 % |
| 2021 | 93.09 % | -859.24 % | -900 % |
| 2020 | 95.64 % | -931.71 % | -950.41 % |
| 2019 | 88.48 % | -1,112.29 % | -1,384.28 % |
| 2018 | 85.42 % | -1,701.59 % | -1,532.1 % |
| 2017 | 93.04 % | -1,633.35 % | -1,559.63 % |
| 2016 | 69.96 % | -2,003.12 % | -1,836.6 % |
| 2015 | 85.16 % | -1,136.78 % | -1,169.7 % |
| 2014 | 81.43 % | -723.81 % | -767.14 % |
| 2013 | 82.9 % | -713.47 % | -756.99 % |
| 2012 | 82.09 % | -791.79 % | -820.15 % |
| 2011 | 72.73 % | -883.64 % | -877.27 % |
| 2010 | 67.8 % | -812.71 % | -804.24 % |
| 2009 | 53.13 % | -2,593.75 % | -2,534.38 % |
| 2008 | 60.52 % | 0 % | 0 % |
| 2007 | 60.52 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2007 | 60.52 % | 0 % | 0 % |
| 2008 | 60.52 % | 0 % | 0 % |
| 2009 | 53.13 % | -2,593.75 % | -2,534.38 % |
| 2010 | 67.8 % | -812.71 % | -804.24 % |
| 2011 | 72.73 % | -883.64 % | -877.27 % |
| 2012 | 82.09 % | -791.79 % | -820.15 % |
| 2013 | 82.9 % | -713.47 % | -756.99 % |
| 2014 | 81.43 % | -723.81 % | -767.14 % |
| 2015 | 85.16 % | -1,136.78 % | -1,169.7 % |
| 2016 | 69.96 % | -2,003.12 % | -1,836.6 % |
| 2017 | 93.04 % | -1,633.35 % | -1,559.63 % |
| 2018 | 85.42 % | -1,701.59 % | -1,532.1 % |
| 2019 | 88.48 % | -1,112.29 % | -1,384.28 % |
| 2020 | 95.64 % | -931.71 % | -950.41 % |
| 2021 | 93.09 % | -859.24 % | -900 % |
| 2022 | 96.76 % | -1,663.57 % | -1,421.19 % |
| 2023 | 60.52 % | -1,384.43 % | -1,235.57 % |
| 2024e | 60.52 % | 0 % | -1,374.84 % |
| 2025e | 60.52 % | -1,436.66 % | -952.44 % |
| 2026e | 60.52 % | -1,319.09 % | -747.92 % |
AB Science Aktienanalyse
What does AB Science do?
AB Science SA is a biopharmaceutical company based in France that specializes in developing therapies for diseases with high medical need and unmet medical demand. The company was founded in 2001 by Alain Moussy and went public on the Paris stock exchange Euronext in 2010. AB Science SA's business model involves independently conducting research and development of new drugs while also building partnerships with other companies or institutions to optimize the value chain from research to commercialization. AB Science SA is divided into different divisions to specifically address the disease areas to be treated, including oncology and neurology. The company aims to develop innovative drugs based on scientific knowledge that meet the needs of patients suffering from severe and complex diseases. An important aspect of AB Science SA's product range is the quality of the products, with the company working on developing effective and safe therapies. A key component of AB Science SA's product range is the tyrosine kinase inhibitor masitinib. This is used in veterinary medicine and is intended to be used in both dogs and cats suffering from allergic, inflammatory, and oncological diseases. Masitinib is a selective inhibitor of tyrosine kinase that contributes to the regulation of signaling pathways found in cancer cells. It is believed that masitinib plays an important role in modulating the immune system and inhibiting cancer cells, although further studies are needed to confirm the potential therapeutic applications of masitinib. AB Science SA has made significant progress in oncology, particularly in the treatment of gastrointestinal stromal tumors and certain types of malignant tumors that are rare forms of cancer. AB Science SA has now submitted both products for an extended approval request (EA) in collaboration with US Regulatory, achieving the most significant success in the company's history. This could expedite the approval of these two products in the United States. In neurology, AB Science SA has also made significant progress and is currently developing products for the treatment of Alzheimer's disease, multiple sclerosis, and Parkinson's disease. In all of these areas, there is a significant unmet need for safe and effective medications, and AB Science SA is committed to addressing this need through the development of innovative therapies. Overall, AB Science SA is a biopharmaceutical company specializing in the development of therapies to combat diseases with high unmet medical needs. In addition to independent research and development, the company aims to build partnerships with other companies and institutions to optimize the value chain from research to commercialization. The main divisions of the company are oncology and neurology, and it has made significant progress in both areas. The increased submission of approval requests is a significant milestone in the company's history and could lead to further advancement within the industry. AB Science ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding AB Science's Profit Margins
The profit margins of AB Science represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of AB Science's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating AB Science's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
AB Science's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When AB Science’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about AB Science stock
How has the profit developed compared to last year?
The profit has increased by -5.48% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does AB Science publish its earnings?
AB Science publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of AB Science?
The profits of AB Science are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of AB Science?
You can learn more about the earnings of AB Science by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does AB Science pay?
Over the past 12 months, AB Science paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AB Science is expected to pay a dividend of 0 EUR.
What is the dividend yield of AB Science?
The current dividend yield of AB Science is .
When does AB Science pay dividends?
AB Science pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AB Science?
AB Science paid dividends every year for the past 0 years.
What is the dividend of AB Science?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is AB Science located?
AB Science is assigned to the 'Health' sector.
Wann musste ich die Aktien von AB Science kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AB Science from 10/2/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.
When did AB Science pay the last dividend?
The last dividend was paid out on 10/2/2024.
What was the dividend of AB Science in the year 2023?
In the year 2023, AB Science distributed 0 EUR as dividends.
In which currency does AB Science pay out the dividend?
The dividends of AB Science are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The AB Science stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von AB Science
Our stock analysis for AB Science Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AB Science Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
